Document is current
Any future updates will be listed below
-
Authors
Denisenko, Elena https://orcid.org/0000-0001-6358-526X
de Kock, Leanne https://orcid.org/0000-0001-7314-1371
Tan, Adeline
Beasley, Aaron B. https://orcid.org/0000-0001-5727-7463
Beilin, Maria
Jones, Matthew E.
Hou, Rui
Muirí, Dáithí Ó
Bilic, Sanela
Mohan, G. Raj K. A.
Salfinger, Stuart
Fox, Simon https://orcid.org/0000-0003-2042-1809
Hmon, Khaing P. W.
Yeow, Yen https://orcid.org/0000-0002-2341-6354
Kim, Youngmi
John, Rhea
Gilderman, Tami S.
Killingbeck, Emily https://orcid.org/0000-0002-5108-5089
Gray, Elin S. https://orcid.org/0000-0002-8613-3570
Cohen, Paul A. https://orcid.org/0000-0002-4860-9232
Yu, Yu
Forrest, Alistair R. R. https://orcid.org/0000-0003-4543-1675
-
Funding
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (GNT1154524)
Cancer Council Western Australia
Cancer research trust
- License Information
-
More Information
Article History
Received: 5 October 2022
Accepted: 26 March 2024
First Online: 3 April 2024
Competing interests
: Paul A. Cohen reports speakers’ honoraria from AstraZeneca and Seqirus, and consultancy fees and stock in Clinic IQ Pty Ltd. Emily Killingbeck is an employee of NanoString Technologies and holds NanoString stock or stock options. All other authors declare no competing interests.
